drugset / Trial / NCT01900496
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
Phase 1
Terminated
6 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This research is being done to study a combination of Brentuximab vedotin and Rituximab for the treatment of relapsed Hodgkin's Lymphoma (HL).
Timeline
- Start
- 2014-06
- Primary completion
- 2017-07
- Completion
- 2017-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brentuximab Vedotin | Monoclonal antibody | 1.8 mg/kg | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |